Feds go after Mylan for scamming Medicaid out of millions on EpiPen pricing

Over the nine or so years that Mylan, Inc. has been selling—and hiking the price—of EpiPens, the drug company has been misclassifying the life-saving device and stiffing Medicaid out of full rebate payments, federal regulators told Ars.

Read More